SLC16A1 and astrocytoma (excluding glioblastoma): We confirmed the diagnostic ability of MCT1 to discriminate GBM patients from healthy subjects (AUC = 0.7558, p < 0.0001) (Figure 7D) or from patients affected by astrocytoma (AUC = 0.7775, p < 0.0001) (Figure 6E) or oligodendrocytoma (AUC = 0.8104, p < 0.0001) (Figure 7F).